Impact Factor 3.845 | CiteScore 3.92
More on impact ›

Mini Review ARTICLE Provisionally accepted The full-text will be published soon. Notify me

Front. Pharmacol. | doi: 10.3389/fphar.2019.01294

Contribution of GABAergic system to non-motor manifestations in premotor and early stages of Parkinson’s Disease

 Ane Murueta-Goyena1*,  Ane Andikoetxea1, Juan Carlos Gomez-Esteban1, 2 and  Inigo Gabilondo1, 3
  • 1Biocruces Bizkaia Health Research Institute, Spain
  • 2University of the Basque Country, Spain
  • 3IKERBASQUE Basque Foundation for Science, Spain

Non-motor symptoms are common in Parkinson’s disease (PD) and they represent a major source of disease burden. Several non-motor manifestations, such as rapid eye movement sleep behavior disorder, olfactory loss, gastrointestinal abnormalities, visual alterations, cognitive and mood disorders, are known to precede the onset of motor signs. Nonetheless, the mechanisms mediating these alterations are poorly understood and probably involve several neurotransmitter systems. The dysregulation of GABAergic system has received little attention in PD, although the spectrum of non-motor symptoms might be linked to this pathway. This Mini Review aims to provide up-to-date information about the involvement of the GABAergic system for explaining non-motor manifestations in early stages of PD. Therefore, special attention is paid to the clinical data derived from patients with isolated REM sleep behavior disorder or drug-naïve patients with PD, as they represent prodromal and early stages of the disease, respectively. This, in combination with animal studies, might help us to understand how the disturbance of the GABAergic system is related to non-motor manifestations of PD.

Keywords: GABA, REM sleep behavior disorder (RBD), hyposmia, Visual symptoms, Gastrointestinal symptoms, neurotransmitters

Received: 16 Jul 2019; Accepted: 09 Oct 2019.

Copyright: © 2019 Murueta-Goyena, Andikoetxea, Gomez-Esteban and Gabilondo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: PhD. Ane Murueta-Goyena, Biocruces Bizkaia Health Research Institute, Barakaldo, Spain,